Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.inger.gob.mx/jspui/handle/20.500.12100/17230
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.rights.license | http://creativecommons.org/licenses/by/4.0 | es_MX |
dc.creator | HILDA MARTINEZ CORIA | es_MX |
dc.creator | XOCHIQUETZALLI MENDOZA ROJAS | es_MX |
dc.creator | ISABEL ARRIETA CRUZ | es_MX |
dc.creator | HECTOR EDUARDO LOPEZ VALDES | es_MX |
dc.date | 2019 | - |
dc.date.accessioned | 2021-08-24T18:46:14Z | - |
dc.date.available | 2021-08-24T18:46:14Z | - |
dc.identifier.uri | http://repositorio.inger.gob.mx/jspui/handle/20.500.12100/17230 | - |
dc.description | Brain aging and neurodegenerative diseases share the hallmarks of slow and progressive loss of neuronal cells. Flavonoids, a subgroup of polyphenols, are broadly present in food and beverage and numerous studies have suggested that it could be useful for preventing or treating neurodegenerative diseases in humans. Dihydromyricetin (DHM) is one of the main flavonoids of some Asian medicinal plants that are used to treat diverse illness. The effects of DHM have been studied in different in vitro systems of oxidative damage and neuroinflammation, as well as in animal models of several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Here we analyzed the most important effects of DHM, including its antioxidant, anti-inflammatory, and neuroprotective effects, as well as its ability to restore GABA neurotransmission and improve motor and cognitive behavior. We propose new areas of research that might contribute to a better understanding of the mechanism of action of this flavonoid, which could help develop a new therapy for aging and age-related brain diseases. | es_MX |
dc.format | Adobe PDF | es_MX |
dc.language | eng | es_MX |
dc.publisher | Frontiers Media | es_MX |
dc.relation | https://www.frontiersin.org/articles/10.3389/fphar.2019.01334/full | es_MX |
dc.relation.requires | Si | es_MX |
dc.rights | Acceso Abierto | es_MX |
dc.source | Frontiers in Pharmacology (1663-9812) Vol. 10 (2019) | es_MX |
dc.subject | MEDICINA Y CIENCIAS DE LA SALUD | es_MX |
dc.subject | Ciencias médicas | es_MX |
dc.subject | Ciencias clínicas | es_MX |
dc.subject | Geriatría | es_MX |
dc.subject | Enfermedades del sistema nervioso | es_MX |
dc.subject | Enfermedades neurodegenerativas | es_MX |
dc.subject | Enfermedades de los ganglios basales | es_MX |
dc.subject | Enfermedad de Huntington | es_MX |
dc.subject | Trastornos parkinsonianos | es_MX |
dc.subject | Enfermedad de Parkinson | es_MX |
dc.subject | Demencia | es_MX |
dc.subject | Enfermedad de Alzheimer | es_MX |
dc.subject | Envejecimiento | es_MX |
dc.subject | Geriatrics | es_MX |
dc.subject | Nervous system diseases | es_MX |
dc.subject | Neurodegenerative diseases | es_MX |
dc.subject | Basal ganglia diseases | es_MX |
dc.subject | Huntington disease | es_MX |
dc.subject | Parkinsonian disorders | es_MX |
dc.subject | Parkinson disease | es_MX |
dc.subject | Dementia | es_MX |
dc.subject | Alzheimer disease | es_MX |
dc.subject | Aging | es_MX |
dc.title | Preclinical Research of Dihydromyricetin for Brain Aging and Neurodegenerative Diseases | es_MX |
dc.type | Artículo | es_MX |
dc.audience | Researchers | es_MX |
dc.creator.id | MACH660202MDFRRL03 | es_MX |
dc.creator.id | MERX950505MDFNJC03 | es_MX |
dc.creator.id | AICI730724MDFRRS06 | es_MX |
dc.creator.id | LOVH620512HDFPLC00 | es_MX |
dc.creator.nameIdentifier | curp | es_MX |
dc.creator.nameIdentifier | curp | es_MX |
dc.creator.nameIdentifier | curp | es_MX |
dc.creator.nameIdentifier | curp | es_MX |
Aparece en las colecciones: | 1. Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Frontiers in Pharmacology (1663-9812) Vol. 10 (2019).pdf | 843.75 kB | Adobe PDF | Visualizar/Abrir |